Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immune-mediated diseases. The company developing rilzabrutinib, an inhibitor that is in ...

Already a Vigil Neuroscience investor, Sanofi has agreed to buy the rest of the biotech’s shares for $8 apiece, representing ...

This browser is no longer supported at MarketWatch. For the best MarketWatch.com experience, please update to a modern browser.

This browser is no longer supported at MarketWatch. For the best MarketWatch.com experience, please update to a modern browser.

Sanofi is to buy Principia Biopharma for up to $3.68 billion, adding a potential multiple sclerosis drug to its pipeline. The French pharma said it will pay $100 per share in cash for San ...

Immune Thrombocytopenia Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the ...

LONDON, GREATER LONDON, UNITED KINGDOM, May 15, 2025 /EINPresswire.com/ -- What Does The Market Size Indicate About The Market Dynamics? The pemphigus vulgaris market size has grown strongly in recent ...

Sanofi has not had the success it was hoping for with its oral BTK inhibitors, acquired as part of its $3.7 billion buyout of Principia Biopharma, but can now point to a win for rilzabrutinib in ...

Sandpoint's Bailey Lancaster recently committed to continue her softball career at Principia College (NCAA Division III) in ...

DUBLIN, May 9, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced presentation of analyses of its previous Phase 3 program ...

* Per the 2022-2023 final release data in IPEDS ‡ The median salary for workers with 10 or more years of experience per Payscale. Principia College is a private liberal arts college in Elsah, Ill.